MA43709A - Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations - Google Patents
Composition pharmaceutique comprenant de l'empagliflozine et ses utilisationsInfo
- Publication number
- MA43709A MA43709A MA043709A MA43709A MA43709A MA 43709 A MA43709 A MA 43709A MA 043709 A MA043709 A MA 043709A MA 43709 A MA43709 A MA 43709A MA 43709 A MA43709 A MA 43709A
- Authority
- MA
- Morocco
- Prior art keywords
- empagliflozin
- pharmaceutical composition
- composition consisting
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309008P | 2016-03-16 | 2016-03-16 | |
| US201662420062P | 2016-11-10 | 2016-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43709A true MA43709A (fr) | 2018-11-28 |
Family
ID=58267120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043709A MA43709A (fr) | 2016-03-16 | 2017-03-13 | Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20170266152A1 (fr) |
| EP (1) | EP3429595A1 (fr) |
| JP (4) | JP7161405B2 (fr) |
| KR (5) | KR20230028568A (fr) |
| CN (3) | CN118286237A (fr) |
| AU (2) | AU2017233889B2 (fr) |
| BR (1) | BR112018016001A2 (fr) |
| CA (1) | CA3017992A1 (fr) |
| CL (1) | CL2018002532A1 (fr) |
| MA (1) | MA43709A (fr) |
| MX (3) | MX2018011088A (fr) |
| PH (1) | PH12018501969A1 (fr) |
| WO (1) | WO2017157816A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| ES2702174T3 (es) | 2013-04-05 | 2019-02-27 | Boehringer Ingelheim Int | Usos terapéuticos de empagliflozina |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PT2986304T (pt) | 2013-04-18 | 2022-02-25 | Boehringer Ingelheim Int | Composição farmacêutica, métodos para o tratamento e suas utilizações |
| BR112020006472A2 (pt) * | 2017-10-02 | 2020-10-06 | Poxel | método para tratamento ou prevenção de insuficiência cardíaca com fração de ejeção preservada (icfep) |
| MX2020013567A (es) | 2018-06-14 | 2021-05-27 | Poxel | Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes. |
| PE20210644A1 (es) | 2018-07-19 | 2021-03-23 | Astrazeneca Ab | METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA |
| WO2020039394A1 (fr) | 2018-08-24 | 2020-02-27 | Novartis Ag | Nouvelles combinaisons de médicaments |
| CN109846898A (zh) * | 2019-02-01 | 2019-06-07 | 同济大学 | 恩格列净在制备治疗和/或预防心肌梗死的药物中的应用 |
| CN114286682A (zh) * | 2019-02-09 | 2022-04-05 | 法码科思莫斯控股有限公司 | 治疗具有心血管不良事件风险的个体的铁缺乏以及用于治疗心房颤动的铁 |
| IT201900006624A1 (it) * | 2019-05-08 | 2020-11-08 | Moret Giannino | Combinazione di canrenone e enalapril per uso nella terapia dei pazienti diabetici. |
| JP2022530575A (ja) * | 2019-08-30 | 2022-06-30 | アストラゼネカ・アクチエボラーグ | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 |
| WO2021049612A1 (fr) * | 2019-09-13 | 2021-03-18 | 国立大学法人富山大学 | Médicament pour améliorer la rétention de fluide dans une insuffisance cardiaque aiguë |
| EP4106744A1 (fr) | 2020-02-17 | 2022-12-28 | Boehringer Ingelheim Vetmedica GmbH | Utilisation d'inhibiteurs de sglt-2 pour la prévention et/ou le traitement de maladies cardiaques chez les félins |
| KR20240041966A (ko) | 2021-07-28 | 2024-04-01 | 베링거잉겔하임베트메디카게엠베하 | 고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도 |
| JP7396579B2 (ja) | 2022-01-31 | 2023-12-12 | 壽製薬株式会社 | 左室駆出率が保たれた心不全に対する医薬組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7723309B2 (en) * | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| CL2008002427A1 (es) * | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| KR101811997B1 (ko) * | 2009-09-30 | 2017-12-26 | 베링거 인겔하임 인터내셔날 게엠베하 | １클로로４（베타ｄ글루코피라노스１일）２（４（（ｓ）테트라하이드로푸란３일옥시）벤질）벤젠의 결정형의 제조방법 |
| US20130035298A1 (en) * | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US9192617B2 (en) * | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) * | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812016A1 (fr) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci |
| US11813275B2 (en) * | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PT2986304T (pt) * | 2013-04-18 | 2022-02-25 | Boehringer Ingelheim Int | Composição farmacêutica, métodos para o tratamento e suas utilizações |
-
2017
- 2017-03-13 US US15/456,631 patent/US20170266152A1/en not_active Abandoned
- 2017-03-13 MA MA043709A patent/MA43709A/fr unknown
- 2017-03-13 CN CN202410254246.5A patent/CN118286237A/zh active Pending
- 2017-03-13 MX MX2018011088A patent/MX2018011088A/es unknown
- 2017-03-13 CN CN201780018512.2A patent/CN109069525A/zh active Pending
- 2017-03-13 EP EP17710524.4A patent/EP3429595A1/fr active Pending
- 2017-03-13 WO PCT/EP2017/055767 patent/WO2017157816A1/fr active Application Filing
- 2017-03-13 KR KR1020237004928A patent/KR20230028568A/ko not_active IP Right Cessation
- 2017-03-13 BR BR112018016001A patent/BR112018016001A2/pt active Search and Examination
- 2017-03-13 KR KR1020237004848A patent/KR20230028565A/ko not_active IP Right Cessation
- 2017-03-13 CA CA3017992A patent/CA3017992A1/fr active Pending
- 2017-03-13 KR KR1020187029941A patent/KR20180122004A/ko not_active IP Right Cessation
- 2017-03-13 KR KR1020247017944A patent/KR20240095321A/ko unknown
- 2017-03-13 KR KR1020237023405A patent/KR20230111262A/ko not_active Application Discontinuation
- 2017-03-13 AU AU2017233889A patent/AU2017233889B2/en active Active
- 2017-03-13 JP JP2018548341A patent/JP7161405B2/ja active Active
- 2017-03-13 CN CN202410254338.3A patent/CN118286238A/zh active Pending
-
2018
- 2018-07-17 US US16/037,052 patent/US20180318251A1/en not_active Abandoned
- 2018-09-05 CL CL2018002532A patent/CL2018002532A1/es unknown
- 2018-09-13 PH PH12018501969A patent/PH12018501969A1/en unknown
- 2018-09-13 MX MX2021010329A patent/MX2021010329A/es unknown
- 2018-09-13 MX MX2022008491A patent/MX2022008491A/es unknown
-
2019
- 2019-02-26 US US16/285,774 patent/US20190350894A1/en not_active Abandoned
-
2020
- 2020-06-18 US US16/904,709 patent/US20210059974A1/en not_active Abandoned
-
2021
- 2021-08-04 JP JP2021128431A patent/JP7454531B2/ja active Active
-
2022
- 2022-03-16 US US17/696,075 patent/US20220211659A1/en active Pending
- 2022-10-05 AU AU2022246392A patent/AU2022246392A1/en active Pending
- 2022-10-14 JP JP2022165221A patent/JP2023001136A/ja active Pending
-
2024
- 2024-03-11 JP JP2024037260A patent/JP2024083347A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230028568A (ko) | 2023-02-28 |
| JP2019508453A (ja) | 2019-03-28 |
| JP7161405B2 (ja) | 2022-10-26 |
| US20170266152A1 (en) | 2017-09-21 |
| AU2022246392A1 (en) | 2022-10-27 |
| KR20180122004A (ko) | 2018-11-09 |
| US20210059974A1 (en) | 2021-03-04 |
| BR112018016001A2 (pt) | 2018-12-18 |
| US20190350894A1 (en) | 2019-11-21 |
| US20180318251A1 (en) | 2018-11-08 |
| CA3017992A1 (fr) | 2017-09-21 |
| US20220211659A1 (en) | 2022-07-07 |
| KR20240095321A (ko) | 2024-06-25 |
| CN118286237A (zh) | 2024-07-05 |
| JP2023001136A (ja) | 2023-01-04 |
| CN109069525A (zh) | 2018-12-21 |
| JP2024083347A (ja) | 2024-06-21 |
| CL2018002532A1 (es) | 2019-01-04 |
| AU2017233889A1 (en) | 2018-08-09 |
| WO2017157816A1 (fr) | 2017-09-21 |
| KR20230111262A (ko) | 2023-07-25 |
| MX2022008491A (es) | 2022-08-02 |
| JP2021181461A (ja) | 2021-11-25 |
| AU2017233889B2 (en) | 2022-07-07 |
| CN118286238A (zh) | 2024-07-05 |
| KR20230028565A (ko) | 2023-02-28 |
| JP7454531B2 (ja) | 2024-03-22 |
| EP3429595A1 (fr) | 2019-01-23 |
| MX2021010329A (es) | 2021-10-13 |
| MX2018011088A (es) | 2018-11-22 |
| PH12018501969A1 (en) | 2019-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43709A (fr) | Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations | |
| MA50753A (fr) | Compositions d'acide nucléique-polypeptide et utilisations de celles-ci | |
| MA50144A (fr) | Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées | |
| MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
| MA46820A (fr) | Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques | |
| MA43308A (fr) | Molécules d'anticorps se liant à april et leurs utilisations | |
| MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
| MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
| MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
| MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
| MA47816A (fr) | Composition pharmaceutique comprenant du sélexipag | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
| MA47494A (fr) | Nouvelles utilisations d'anticorps anti-sirpg | |
| MA44665A (fr) | Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques | |
| MA46742A (fr) | Composition pharmaceutique, méthodes de traitement et leurs utilisations | |
| MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
| FR3032353B1 (fr) | Composition pharmaceutique et dispositif pour le traitement de la douleur | |
| MA43361A (fr) | Composition pour le soin et la protection de cultures | |
| MA47459A (fr) | Anticorps anti-tryptase, compositions les contenant et leurs utilisations | |
| MA43556A (fr) | Combinaisons d'un anticorps ox40 et d'un modulateur tlr4 et utilisations de celles-ci | |
| MA52644A (fr) | Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation | |
| MA40427A (fr) | Composition comprenant des substances naturelles et/ou des extraits | |
| MA47516A (fr) | Composition pharmaceutique | |
| MA51147A (fr) | Associations d'anticorps anti-c5 et utilisations associées |